TiCARos’ mission is to create a paradigm shift in the CAR-T therapeutics landscape that could achieve a complete cure for both intractable hematologic malignancies and advanced solid tumors ...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T ...

The gist of this is that the technology, if deployed with clinical success, would disrupt the CAR-T landscape. I will be going over several reasons why below, but the promise of this is another ...

With the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers of ...

Bristol Myers Squibb remains the dominant player in the CAR-T landscape with two already marketed products—Abecma (idecabtagene vicleucel) for multiple myeloma and Breyanzi (lisocabtagene ...

What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T therapies ...